Genotype Differences and Hydroxyurea Utilization Among Adults With Moderate to Severe Sickle Cell Disease.

ABSTRACT:

Backgrounds

Hydroxyurea (HU) remains underutilized in adults with sickle cell disease (SCD) despite proven benefits. Current HU guidelines primarily target sickle cell anemia (SCA), overlooking other genotypes.

Objectives

This study examined HU utilization patterns across genotypes among adults considered to have moderate to severe SCD manifestations by the 2014 National Heart, Lung, and Blood Institute (NHLBI) guideline criteria and identified factors associated with early HU use.

Methods

This retrospective cohort study analyzed electronic health records from the University of Pittsburgh Medical Center (2014-2024) of adults with SCD experiencing three or more vaso-occlusive crises (VOCs) within 12 months. HU utilization rates, stratified by genotype, were assessed at

SUBMITTER: Cheng SH 

PROVIDER: S-EPMC12800872 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature